PhytoMedical Technologies, Inc.
(Symbol: PYTO), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cancer and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds.

Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

To Learn More Click Here

CANCER
PhytoMedical is developing a new class of agents designed to bind to DNA and kill cancer cells.

Scientists are testing and synthesizing anti-tumor agents with a ‘cytotoxic’ or poisonous affinity for cancer cells that are designed to bind more tightly to DNA than conventional drugs. DNA is the blueprint of life for the cancer cell, and such binding stops its replication which prevents the growth of the cancer cell and leads to its death.

Read More

DIABETES
PhytoMedical is developing an entirely new, innovative class of diabetes compounds that are patterned after polyphenols found in cinnamon, shown in numerous published studies to favorably affect type-2 diabetes.

These compounds can significantly lower blood sugar by an average of 18-29%, triglycerides by 23-30%, LDL (or “bad”) cholesterol by 7-27% and total cholesterol by 12-26%. Most importantly, no side effects were reported in the study.

Read More